The crude event rate per 1000 person-years (95% CI) for each endpoint in osteoarthritis and rheumatoid arthritis patients.
| Primary Prevention | Secondary Prevention | |||
|---|---|---|---|---|
| Statin-exposed | Statin-unexposed | Statin-exposed | Statin-unexposed | |
| Osteoarthritis | ||||
| APTC endpoint | 13.5 (9.7–18.9) | 22.1 (15.8–30.9) | 37.7 (24.0–59.1) | 86.7 (53.9–139.5) |
| Nonfatal MI | 4.6 (2.6–8.1) | 6.3 (3.4–11.7) | 9.4 (3.9–22.7) | 29.0 (13.0–64.5) |
| Nonfatal stroke | 4.5 (2.6–8.0) | 7.6 (4.3–13.5) | 5.5 (1.8–16.9) | 15.3 (4.9–47.5) |
| CV death | 7.8 (5.0–12.2) | 16.7 (11.4–24.3) | 18.7 (9.7–35.9) | 69.7 (41.3–117.6) |
| All-cause mortality | 16.4 (12.1–22.4) | 39.3 (30.8–50.2) | 27.2 (15.8–46.8) | 113.9 (75.7–171.3) |
| Rheumatoid arthritis | ||||
| APTC endpoint | 14.2 (7.6–26.3) | 24.3 (15.5–38.1) | 47.6 (24.8–91.5) | 81.6 (30.6–217.5) |
| Nonfatal MI | 6.8 (2.8–16.2) | 11.3 (5.9–21.8) | 14.1 (4.5–43.7) | 38.5 (9.6–153.8) |
| Nonfatal stroke | 3.9 (1.2–12.0) | 6.5 (2.7–15.6) | — | — |
| CV death | 8.3 (3.7–18.5) | 16.3 (9.4–28.0) | 43.0 (21.5–86.0) | 81.1 (26.1–251.4) |
| All-cause mortality | 31.9 (21.2–48.0) | 47.0 (34.2–64.6) | 78.1 (47.1–129.6) | 111.1 (41.7–296.1) |
APTC: Anti-platelet Trialists’ Collaboration; MI: myocardial infarction; CV: cardiovascular.